<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795496</url>
  </required_header>
  <id_info>
    <org_study_id>232685</org_study_id>
    <nct_id>NCT00795496</nct_id>
  </id_info>
  <brief_title>Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up</brief_title>
  <official_title>Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will contact 64 patients with atopic dermatitis (AD) who participated in a
      long-term tacrolimus ointment trial in Helsinki 10 years ago, and ask them to participate in
      this follow-up study. The investigators will do the same tests as 10 years ago, i.e.
      bronchial hyperreactivity, skin prick tests, serum-IgE, Mantoux-test (2 TU), and
      questionnaires about asthma and allergic rhinitis symptoms. The investigators also collect
      data about their AD medication during the last 10 years.

      The investigators hypothesis is that when the skin condition improves in patients with AD the
      brochial hyperreactivity improves. The investigators also want to study whether different
      treatments play a role in the development or resolution of bronchial hyperreactivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will by letters and telephone contact all patients (n=64) who fulfill the inclusion
      criteria for this study.

      The testing in the study (bronchial hyperreactivity, skin prick testing, serum IgE) is
      cross-sectional, but we retrospectively collect data from the last 10 years about the skin
      condition and medication for atopic diseases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchial hyperreactivity</measure>
    <time_frame>10 year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin prick tests</measure>
    <time_frame>10 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum-IgE</measure>
    <time_frame>10-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mantoux-test</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>AD patients</arm_group_label>
    <description>AD patients who fulfill the inclusion criteria for the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Histamine provocation</intervention_name>
    <description>A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.</description>
    <arm_group_label>AD patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin prick tests</intervention_name>
    <description>Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.</description>
    <arm_group_label>AD patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serum IgE blood testing</intervention_name>
    <description>One blood test to measure total serum IgE</description>
    <arm_group_label>AD patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mantoux-testing</intervention_name>
    <description>Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.</description>
    <arm_group_label>AD patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum is collected for measurement of IgE
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators invite all patients who participated in the FG-506-06-21 tacrolimus
        ointment study, and who at baseline in that study were tested for bronchial
        hyperreactivity.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has participated in the FG-506-06-21 study in Helsinki

          -  Patient was tested for bronchial hyperreactivity in the years 1998-2000

          -  Patient gives signed informed consent to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sakari Reitamo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin- and Allergy Hospital, Dep. of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin- and Allergy Hospital, Department of Dermatology</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Virtanen H, Remitz A, Malmberg P, Rytil√§ P, Metso T, Haahtela T, Reitamo S. Topical tacrolimus in the treatment of atopic dermatitis--does it benefit the airways? A 4-year open follow-up. J Allergy Clin Immunol. 2007 Dec;120(6):1464-6. Epub 2007 Oct 1.</citation>
    <PMID>17910892</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>April 19, 2011</last_update_submitted>
  <last_update_submitted_qc>April 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sakari Reitamo, MD, PhD, Specialist in Dermatology, Acting Professor</name_title>
    <organization>Helsinki University Central Hospital, Department of Dermatology</organization>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Bronchial hyperreactivity</keyword>
  <keyword>Skin prick tests</keyword>
  <keyword>Serum IgE</keyword>
  <keyword>Mantoux test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

